Duchenne muscular dystrophy laboratory findings

Jump to navigation Jump to search

Duchenne muscular dystrophy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Duchenne muscular dystrophy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Duchenne muscular dystrophy laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Duchenne muscular dystrophy laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Duchenne muscular dystrophy laboratory findings

CDC on Duchenne muscular dystrophy laboratory findings

Duchenne muscular dystrophy laboratory findings in the news

Blogs on Duchenne muscular dystrophy laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Duchenne muscular dystrophy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Laboratory findings consistent with the diagnosis of Duchenne muscular dystrophy include increased level of CPK, transaminases, and aldolase.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Duchenne muscular dystrophy include:[1][2][3][4]

NOTE: After few years, as the disease progress and muscle cells are replaced by fat, these enzymes will be back to their normal levels.

References

  1. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, Kneile K, Dunn DM, Duval B, Aoyagi A, Hamil C, Mahmoud M, Roush K, Bird L, Rankin C, Lilly H, Street N, Chandrasekar R, Weiss RB (March 2012). "Evidence-based path to newborn screening for Duchenne muscular dystrophy". Ann. Neurol. 71 (3): 304–13. doi:10.1002/ana.23528. PMID 22451200.
  2. McMillan HJ, Gregas M, Darras BT, Kang PB (January 2011). "Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy". Pediatrics. 127 (1): e132–6. doi:10.1542/peds.2010-0929. PMID 21149430.
  3. Okinaka, S. (1961). "Serum Creatine Phosphokinase". Archives of Neurology. 4 (5): 520. doi:10.1001/archneur.1961.00450110050006. ISSN 0003-9942.
  4. Soltan, Hubert C.; Blanchaer, Marcel C. (1959). "Activity of serum aldolase and lactic dehydrogenase in patients affected with duchenne muscular dystrophy and in their immediate relatives". The Journal of Pediatrics. 54 (1): 27–33. doi:10.1016/S0022-3476(59)80033-0. ISSN 0022-3476.

Template:WH Template:WS